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The pharmacokinetics of ceftizoxime (CZX) and of cefotaxime (CTX) were studied in five children and five 
adults after orthotopic liver transplantation (OLT). Delayed clearance of CZX (clearance of 0.21 to 1.26 ml/min 
per kg [body weight)) and CTX (clearance of 0.40 to 1.49 ml/min per kg) occurred in 7 of the 10 OLT patients. 
We conclude that abnormal CZX and CTX clearance is common after OLT and may be associated with 
minimal change in serum creatinine. 
Cefotaxime (CTX) in combination with ampicillin is used 
in our institution for surgical prophylaxis before and after 
orthotopic liver transplantation (OLT). The objective of this 
study was to evaluate the disposition of CTX and cefti-
zoxime (CZX), the accumulation of the des acetyl metabolite 
of CTX (DACTX), and the relationship of the 
pharmacokinetics of these compounds to renal and hepatic 
function after OLT. 
Five children, 14 to 62 months old, and five adults were 
enrolled in the study within 72 h after OLT. The research 
protocol was approved by the Human Rights Committee, 
University of Pittsburgh, Pittsburgh, Pa., and parental or 
patient consent was obtained before subject enrollment. 
Medications at the time of study included CTX, cyclo-
sporine, methylprednisolone, ampicillin, nystatin, mor-
phine, hydralazine, furosemide, captopril, and oral antacids. 
CTX at approximately 25 mg/kg (body weight) per dose for 
children and 1.0 g per dose for adults was administered 
intravenously before surgery and continued every 6 h during 
the postoperative period. A single dose of CZX in the same 
amount was substituted for a scheduled CTX dose and 
infused intravenously. Blood samples were obtained before 
and at 0.5, 1, 2, 4. 6, 6.5, 7, 8, 10, and 12 h after the initiation 
of the CZX or CTX infusion. The samples were centrifuged, 
and the plasma was separated and frozen at -70°C. All the 
samples were assayed within 8 weeks of study. 
Plasma samples for measurement of CZX, CTX, and 
DACTX content were assayed in duplicate by using a 
modification of a previously described high-pressure liquid 
chromatographic method (4). The resultant peaks of 
DACTX, CZX, and CTX were detected at 4.0, 7.2, and 13.5 
min, respectively. Of the other drugs which the patients 
were receiving, only ampicillin was detected under the 
above-stated conditions, and it was separated from the 
compounds of interest. 
The method of reverse superposition was used to generate 
single-dose curves for CTX from the plasma concentration-
time data (1). The elimination rate constants for CZX and 
CTX were calculated by linear regression of the natural 
logarithm of the plasma concentration versus time for 
postadministration datum points. The area under the plasma 
concentration-time curve from 0 h to infinity was calculated 
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by using the trapezoidal method. Systemic drug clearance 
was determined by dividing the dose administered by the 
area under the curve. The apparent volume of distribution at 
steady state was calculated by the statistical moment theory 
(2). 
The characteristics of the patients are shown in Table 1. 
Higher serum bilirubin values with slow improvement in 
hepatic function were noted postoperatively in pediatric 
patient 1. In the adult group, the liver of patient 9 may have 
had some ischemic damage during harvesting. In the pediat-
ric patients, peak concentrations of 33.9 to 67.2 f.Lg/ml were 
measured after the administration of a single dose of CZX, 
with a 6-h average concentration of 11.6 J..Lg/ml (range, <1.0 
to 26.0 f.Lg/ml). After the 1.0-g CZX dose in adults, peak 
concentrations ranged from 74.0 to 98.8 J..Lg/ml, with 6-h 
concentrations of 8.2 to 42.0 J..Lg/ml. Peak concentrations of 
45 to 112.5 J..Lg/ml were measured in the pediatric patients 
after the administration of mUltiple doses of CTX, with a 6-h 
average concentration of 11.2 f.Lg/ml (range, 1.0 to 34.5 
f.Lg/ml). In the adults, peak concentrations of CTX ranged 
from 66.0 to 169.5 f.Lg/ml, with 6-h concentrations of 5.1 to 
72.0 J..Lg/ml after the 1.0-g CTX dose. Calculated phar-
macokinetic parameters for CTX and CZX are shown in 
Table 2. 
Highly variable concentrations of the metabolite DACTX 
were detected in the 10 subjects. No evidence of DACTX 
was found in serum from patient 1, who demonstrated 
delayed recovery ofliver function. Accumulation ofDACTX 
(>20 f.Lg/ml) during the dosage interval was documented in 
TABLE 1. Patient demographicsa 
Wt Total SGOT SGPT Creatinine Patient Age (kg) bilirubin (Ulml) (Ulm!) (mgldl) (mgldl) 
33 mo 15.0 22.6 1,038 634 0.2 
2 30 mo 10.9 1.6 362 439 0.2 
3 17 mo 12.0 5.5 704 663 0.2 
4 62 rna 17.9 8.1 840 813 0.6 
5 14 rna 8.7 8.7 1,502 769 0.7 
6 53 yr 60.1 10.8 203 242 2.1 
7 49 yr 62.0 14.8 448 552 1.4 
8 45 yr 59.9 7.4 127 135 4.2 
9 51 yr 79.6 3.7 2.528 1.668 1.6 
10 23 yr 73.5 8.5 772 864 1.0 
a SOOT, Serum glutamic oxalacetic transaminase: SOPT, serum glutamic 
pyruvic transaminase. 
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TABLE 2. Pharmacokinetic parameters for CZX and CTxa 
CZX CTX 
Patient CL V" CL V" 1112 (h) (rn1Imin Oiters/kg) 111' (h) (mil min Oiters/kg) per kg) per kg) 
1 1.7 5.88 0.60 1.4 6.64 0.53 
2 2.7 2.63 0.54 1.2 4.65 0.43 
3 1.5 5.59 0.63 1.8 2.75 0.30 
4 5.8 0.62 0.31 2.3 0.95 0.19 
5 11.7 0.56 0.55 5.3 0.83 0.37 
6 12.1 0.40 0.42 4.9 0.75 0.32 
7 5.7 0.68 0.33 3.1 0.91 0.23 
8 14.9 0.21 0.27 7.1 0.40 0.24 
9 4.1 1.26 0.37 2.2 1.49 0.22 
10 5.2 0.88 0.35 3.2 1.31 0.34 
" 1112. half·life; CL, clearance; V,,, volume of distribution at steady state. 
patient 5 (Fig. 1) and in patients 4, 6, and 8 in association 
with impaired renal function. 
A 45% incidence of bacteremia has been reported after 
OLT during a 24-month period at our institution (5). The 
most frequent infecting pathogens were Enterococcus sp., 
Staphylococcus sp., Escherichia coli, Citrobacter sp., and 
Bacteroides sp. The combination of ampicillin plus an ex-
tended-spectrum cephalosporin provides acceptable antibac-
terial coverage for these organisms. 
The clearance rate of CTX was impaired in our OL T 
patients beyond normal predictions based on renal function. 
Matzke and co-workers (3) defined a clear relationship 
between renal function and CTX clearance. Although none 
of our OL T patients should have had severe renal impair-
ment based on serum creatinine, two children and all of the 
adults had CTX clearance rates paralleling the severe renal 
insufficiency group described by Matzke et al. The explana-
tion for the discrepancy between. serum creatinine and CTX 
clearance is unknown. 
CTX regimens with doses of 25 mg/kg at 6-h intervals 
resulted in acceptable peak and trough concentrations in 
plasma in our pediatric subjects. Standard l.O-g doses of 
CTX should be administered to adult OLT patients at 8-h 
intervals. Our study supports a dosage interval of 12 h for 
CZX in OLT patients, but clinical experience with CZX in 
OLT patients must be acquired before definite recommen-
dations can be made. 
At least 16 centers in North America now perform OLT 
operations. The drug regimens of 0 L T patients are complex 
and frequently contain cephalosporin antibiotics for prophy-
lactic or therapeutic treatment. We demonstrated that the 
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FIG. 1. Plasma concentration versus time in patient 5. A dose of 
25 mg of CZX per kg (D) was given at time 0, and 25 mg of CTX per 
kg (0) was given at 6 h. DACTX (.6.) is also shown. 
clearance of CTX was decreased in OL T patients and was 
not in proportion to changes in serum creatinine. CZX 
half-lives are longer than those of CTX, so a longer dosage 
interval is necessary. 
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